AVTX (Avalo Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $17.68
GF Value $0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics FCF Margin %?

Avalo Therapeutics AVTX -1.78% 23 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates AVTX with a GF Score™ of 23/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, Avalo Therapeutics ranks worse than 98.12% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Avalo Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-17.69 Mil. Avalo Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Avalo Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Avalo Therapeutics's current FCF Yield % is -6.42%.

The historical rank and industry rank for Avalo Therapeutics's FCF Margin % or its related term are showing as below:

AVTX' s FCF Margin % Range Over the Past 10 Years
Min: -101172.88   Med: -936.53   Max: 45.14
Current: -101172.88

During the past 13 years, the highest FCF Margin % of Avalo Therapeutics was 45.14%. The lowest was -101172.88%. And the median was -936.53%.

AVTX's FCF Margin % is ranked worse than
98.12% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs AVTX: -101172.88

Avalo Therapeutics FCF Margin % Related Terms

Avalo Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics FCF Margin % Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,315.39 -148.72 -1,594.59 -11,123.81 -87,216.95

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -24,145.76 0.00

AVTX vs EVMN, TBPH, VOR: FCF Margin % Comparison

For the Biotechnology subindustry, Avalo Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalo Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's FCF Margin % falls into.


AVTX
23GF Score
Avalo Therapeutics Inc AVTX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Avalo Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-51.458/0.059
=-87,216.95 %

Avalo Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-17.691/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Avalo Therapeutics (AVTX) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Avalo Therapeutics and its competitors. According to the industry distribution chart, Avalo Therapeutics ranks #941 out of 959 companies in the Biotechnology industry, placing it in the top 98.1%.
Is Avalo Therapeutics' FCF Margin % too high?
Avalo Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Avalo Therapeutics ranks #941 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avalo Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' FCF Margin % compare to EVMN and TBPH?
According to the Biotechnology industry distribution chart, Avalo Therapeutics ranks #941 out of 959 companies for FCF Margin %. This places Avalo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (AVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $17.68 — trading 58833.3% above its estimated fair value. The current FCF Margin % is 0.00%. Avalo Therapeutics' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Avalo Therapeutics (AVTX), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $17.68 is trading 58833.3% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • FCF Margin %: 0.00%
  • GF Value™: $0.03 vs. price of $17.68 (58833.3% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.68
Price
$0.03
GF Value